Print Issue: July 01, 2007

Another Renal Cancer Drug Reaches Phase II

Rexahn Pharmaceuticals, Inc., of Rockville, Md., has announced that it has received approval to begin a phase II study for its lead oncology compound, Archexin (formerly known as RX-0201), in patients with advanced renal cell carcinoma.

Drug May Reduce Proteinuria

SAN FRANCISCO—A new study found that converting from tacrolimus/sirolimus (TAC/SRL) to TAC/enteric-coated mycophenolic sodium (EC-MPS) may reduce proteinuria in renal transplant patients.

Next post in News